Lack of cost-effectiveness of omalizumab.
Miller
Thomas P
TP
Reeves
Mathew J
MJ
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D000069444:Omalizumab
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab